Wolfe Research analyst Mike Polark initiated coverage of Beta Bionics (BBNX) with an Outperform rating and $20 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Positive Developments and Strategic Advancements Drive Buy Rating for Beta Bionics, Inc.
- Beta Bionics Q1 2025 Earnings: Strong Growth and Optimism
- Strong Performance and Growth Potential: Buy Rating for Beta Bionics, Inc.
- Beta Bionics price target lowered to $15 from $20 at Baird
- Positive Developments and Strong Financial Performance Drive Buy Rating for Beta Bionics, Inc.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue